SUSTAINED INHIBITION OF THE VESSEL WALL PLATELET INTERACTION AFTER DEEP CORONARY-ARTERY INJURY BY TEMPORARY INHIBITION OF THE PLATELET GLYCOPROTEIN IIB IIIA RECEPTOR

被引:28
作者
BATES, ER
WALSH, DG
MU, DX
ABRAMS, GD
LUCCHESI, BR
机构
[1] UNIV MICHIGAN, SCH MED, DEPT INTERNAL MED, ANN ARBOR, MI 48104 USA
[2] UNIV MICHIGAN, SCH MED, DEPT PHARMACOL, ANN ARBOR, MI 48104 USA
[3] UNIV MICHIGAN, SCH MED, DEPT PATHOL, ANN ARBOR, MI 48104 USA
关键词
ELECTROLYTIC INJURY; PLATELET AGGREGATION; THROMBOSIS; THROMBOLYTIC THERAPY;
D O I
10.1097/00019501-199201000-00010
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: There purpose of this investigation was to determine whether a vascular surface overlying deep arterial injury could become nonthrombogenic after temporary, but complete, inhibition of platelet reactivity. Methods: The circumflex coronary arteries of 18 dogs were instrumented with a Doppler flow probe and subjected to an intracoronary stimulation electrode and a ligature stenosis. One day later, group 1 animals received placebo and group 2 animals received an intravenous injection of the 7E3 F(ab')2 monoclonal antibody (0.8 mg/kg) to the platelet glycoprotein llb/llla receptor. A deep electrolytic injury of the coronary artery was then produced by applying a 100-mu-A direct anodal current to the intimal surface of the vessel for 3 hours. Results: Compared with group 1, thrombotic arterial occlusion in group 2 was reduced significantly at 3 hours (6/9 vs 0/9, P = 0.01), at 24 hours (9/9 vs 0/9, P = 0.001), and after 6 days (9/9 vs 2/9, P = 0.01). Mortality was reduced in group 2 at 8 hours (5/9 vs 0/9, P = 0.035), at 24 hours (9/9 vs 0/9, P = 0.001), and after 6 days (9/9 vs 1/9, P = 0.001). Myocardial infarction occurred more frequently in group 1 (9/9 vs 4/9, P = 0.05). Infarct size, expressed as a percent of left ventricular mass was larger in group 1 (18.9% +/- 3.4% vs 7.9% +/- 3.3%, P = 0.07). Platelet aggregation to arachidonic acid was inhibited completely for at least 3 hours in group 2 and did not return to normal until day 4. Conclusions: Inhibition of in vivo platelet aggregation with the 7E3 F(ab')2 monoclonal antibody prevented acute coronary artery occlusion and reduced the incidence of late thrombotic occlusion, infarct size, and mortality. Interaction of the injured vascular wall with circulating platelets is a time-limited event, with the vessel becoming relatively nonthrombogenic despite extensive damage to the intimal and subintimal structures and a progressive return of platelet reactivity.
引用
收藏
页码:67 / 76
页数:10
相关论文
共 40 条
[1]  
[Anonymous], 1988, LANCET, V2, P349
[2]   ASPIRIN AND DIPYRIDAMOLE IN THE PREVENTION OF ACUTE CORONARY-THROMBOSIS COMPLICATING CORONARY ANGIOPLASTY [J].
BARNATHAN, ES ;
SCHWARTZ, JS ;
TAYLOR, L ;
LASKEY, WK ;
KLEAVELAND, JP ;
KUSSMAUL, WG ;
HIRSHFELD, JW .
CIRCULATION, 1987, 76 (01) :125-134
[3]   A MONOCLONAL-ANTIBODY AGAINST THE PLATELET GLYCOPROTEIN-IIB/IIIA RECEPTOR COMPLEX PREVENTS PLATELET-AGGREGATION AND THROMBOSIS IN A CANINE MODEL OF CORONARY ANGIOPLASTY [J].
BATES, ER ;
MCGILLEM, MJ ;
MICKELSON, JK ;
PITT, B ;
MANCINI, GBJ .
CIRCULATION, 1991, 84 (06) :2463-2469
[4]   ROLE OF BLOOD-FLOW IN PLATELET ADHESION, FIBRIN DEPOSITION, AND FORMATION OF MURAL THROMBI [J].
BAUMGARTNER, HR .
MICROVASCULAR RESEARCH, 1973, 5 (02) :167-179
[5]   CORRELATION OF PLASMA SEROTONIN CHANGES WITH PLATELET-AGGREGATION IN AN INVIVO DOG-MODEL OF SPONTANEOUS OCCLUSIVE CORONARY THROMBUS FORMATION [J].
BENEDICT, CR ;
MATHEW, B ;
REX, KA ;
CARTWRIGHT, J ;
SORDAHL, LA .
CIRCULATION RESEARCH, 1986, 58 (01) :58-67
[6]   EFFECT OF HEPARIN ON CORONARY ARTERIAL PATENCY AFTER THROMBOLYSIS WITH TISSUE PLASMINOGEN-ACTIVATOR IN ACUTE MYOCARDIAL-INFARCTION [J].
BLEICH, SD ;
NICHOLS, TC ;
SCHUMACHER, RR ;
COOKE, DH ;
TATE, DA ;
TEICHMAN, SL .
AMERICAN JOURNAL OF CARDIOLOGY, 1990, 66 (20) :1412-1417
[7]   INVIVO MODELS OF ARTERIAL THROMBOSIS AND THROMBOLYSIS [J].
BUSH, LR ;
SHEBUSKI, RJ .
FASEB JOURNAL, 1990, 4 (13) :3087-3098
[8]   ASPIRIN, SULFINPYRAZONE, OR BOTH IN UNSTABLE ANGINA - RESULTS OF A CANADIAN MULTICENTER TRIAL [J].
CAIRNS, JA ;
GENT, M ;
SINGER, J ;
FINNIE, KJ ;
FROGGATT, GM ;
HOLDER, DA ;
JABLONSKY, G ;
KOSTUK, WJ ;
MELENDEZ, LJ ;
MYERS, MG ;
SACKETT, DL ;
SEALEY, BJ ;
TANSER, PH .
NEW ENGLAND JOURNAL OF MEDICINE, 1985, 313 (22) :1369-1375
[9]   EVALUATION OF COMBINATION THROMBOLYTIC THERAPY AND TIMING OF CARDIAC-CATHETERIZATION IN ACUTE MYOCARDIAL-INFARCTION - RESULTS OF THROMBOLYSIS AND ANGIOPLASTY IN MYOCARDIAL-INFARCTION PHASE-5 RANDOMIZED TRIAL [J].
CALIFF, RM ;
TOPOL, EJ ;
STACK, RS ;
ELLIS, SG ;
GEORGE, BS ;
KEREIAKES, DJ ;
SAMAHA, JK ;
WORLEY, SJ ;
ANDERSON, JL ;
HARRELSONWOODLIEF, L ;
WALL, TC ;
PHILLIPS, HR ;
ABBOTTSMITH, CW ;
CANDELA, RJ ;
FLANAGAN, WH ;
SASAHARA, AA ;
MANTELL, SJ ;
LEE, KL .
CIRCULATION, 1991, 83 (05) :1543-1556
[10]  
COLLER BS, 1985, BLOOD, V66, P1456